Literature DB >> 6291746

Positive correlation between high aryl hydrocarbon hydroxylase activity and primary lung cancer as analyzed in cryopreserved lymphocytes.

R E Kouri, C E McKinney, D J Slomiany, D R Snodgrass, N P Wray, T L McLemore.   

Abstract

Blood samples from closely monitored patients at the Veterans Administration Hospital in Houston, Texas, were collected, coded, and sent to Microbiological Associates over an 8-month period. Lymphocytes were isolated and cryopreserved at -190 degrees. Lymphocyte samples were simultaneously thawed, phytohemagglutinin activated, and analyzed for benz(a)anthracene-induced aryl hydrocarbon hydroxylase (AHH) levels, [3H]thymidine incorporation, and reduced nicotinamide adenine dinucleotide-dependent cytochrome b5 (cytochrome c) reductase activity. Determinations were made at both 96 and 120 hr in culture, and peak activities were compared among a total of 51 individuals who expressed such lesions as squamous cell carcinomas (22%), adenocarcinomas (14%), oat cell carcinomas (6%), chronic obstructive pulmonary disease (22%), and other nonmalignant diseases. Of the 14 highest AHH/cytochrome c activities observed, all were found in patients with primary lung cancer. Mean AHH/cytochrome c activities were 0.89 for lung cancer patients (a total of 21) and 0.47 for noncancer patients (a total of 30) (p less than 0.001). No relationship was observed between AHH/cytochrome c activity and age of patient, numbers of cigarettes smoked, family history of cancer, location or histological type of tumor, or level of phytohemagglutinin blastogenesis ([3H]thymidine cpm/cytochrome c). Whether the higher AHH levels are the cause or the result of the primary lung cancer remains to be determined.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6291746

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  44 in total

Review 1.  Development of analytical technology in pharmacogenetic research.

Authors:  Ann K Daly
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-09-25       Impact factor: 3.000

Review 2.  Molecular basis of polymorphic drug metabolism.

Authors:  A K Daly
Journal:  J Mol Med (Berl)       Date:  1995-11       Impact factor: 4.599

3.  Carcinogenicity of exposure to industrial chemicals. Misconceptions and realities.

Authors:  A J McMichael
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 Nov-Dec

4.  Cell-specific induction of mouse Cyp1a1 mRNA during development.

Authors:  A Dey; H Westphal; D W Nebert
Journal:  Proc Natl Acad Sci U S A       Date:  1989-10       Impact factor: 11.205

Review 5.  Pharmacogenetic perspectives on susceptibility to toxic industrial chemicals.

Authors:  E S Vesell
Journal:  Br J Ind Med       Date:  1987-08

6.  The use of computers in the safety evaluation of drugs and other chemicals.

Authors:  C Ioannides; D F Lewis; D V Parke
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1994 Jul-Sep       Impact factor: 2.441

7.  Partial characterization of the human CYP1A1 negatively acting transcription factor and mutational analysis of its cognate DNA recognition sequence.

Authors:  P D Boucher; M P Piechocki; R N Hines
Journal:  Mol Cell Biol       Date:  1995-09       Impact factor: 4.272

8.  Identification of an inducible form of cytochrome P-450 in human liver.

Authors:  P B Watkins; S A Wrighton; P Maurel; E G Schuetz; G Mendez-Picon; G A Parker; P S Guzelian
Journal:  Proc Natl Acad Sci U S A       Date:  1985-09       Impact factor: 11.205

9.  Detection of CYP1A1 gene polymorphism using designed RFLP and distributions of CYP1A1 genotypes in Japanese.

Authors:  T Oyama; T Mitsudomi; T Kawamoto; A Ogami; T Osaki; Y Kodama; K Yasumoto
Journal:  Int Arch Occup Environ Health       Date:  1995       Impact factor: 3.015

10.  CYP1A1 gene polymorphisms increase lung cancer risk in a high-incidence region of Spain: a case control study.

Authors:  Carmen San Jose; Agustin Cabanillas; Julio Benitez; Juan Antonio Carrillo; Mercedes Jimenez; Guillermo Gervasini
Journal:  BMC Cancer       Date:  2010-08-30       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.